Evidence map›Paper›PMID 40119410›Full record

ArticleBMC pharmacology & toxicology2025

Trends in drug-drug interactions for new drug clinical trials in China over the past 10 years (2013-2022).

Jianxiong Zhang, Jingxuan Wu, Jiangshuo Li, Meixia Liu, Shaodan Liu, Ruirui He, Ruihua Dong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jianxiong ZhangResearch Ward, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong An Road, Xicheng District, Beijing, 100050, China.
Jingxuan WuResearch Ward, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong An Road, Xicheng District, Beijing, 100050, China.
Jiangshuo LiResearch Ward, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong An Road, Xicheng District, Beijing, 100050, China.
Meixia LiuDepartment of Statistics and Clinical Pharmacology, Center for Drug Evaluation, National Medical Products Administration, Economic-Technological Development Area, No. 22 Guangde Street, Beijing, 100076, China.
Shaodan LiuDepartment of Statistics and Clinical Pharmacology, Center for Drug Evaluation, National Medical Products Administration, Economic-Technological Development Area, No. 22 Guangde Street, Beijing, 100076, China.
Ruirui HeDepartment of Statistics and Clinical Pharmacology, Center for Drug Evaluation, National Medical Products Administration, Economic-Technological Development Area, No. 22 Guangde Street, Beijing, 100076, China. herr@cde.org.cn.
Ruihua DongResearch Ward, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong An Road, Xicheng District, Beijing, 100050, China. ruihua_dong_rw@163.com.ORCID 0000-0003-3463-5023

Funding

National Key Research and Development Program of China No. 2024YFF1207000
6 · The paper itself

Abstract

The number of drug-drug interaction (DDI) clinical trials in China has increased rapidly in recent years. The aim of this study was to summarize and analyze DDI clinical trials in China over the past 10 years. We conducted a cross-sectional study of DDI clinical trials registered in the Chinese Center for Drug Evaluation (CDE) from September 6, 2013 to December 31, 2022. All related registration information disclosed on the CDE website were summarized and analyzed. Although the number of DDI clinical trials conducted before 2017 was relatively low, it increased markedly after 2017. The average duration of DDI clinical trials was 85.83 ± 100.99 days from 2013 to 2019 and 107.16 ± 98.57 days from 2020 to 2022. The duration of rifampicin use was 5-19 days, and the investigational drug was administered after 5-14 days of rifampicin use. Itraconazole was administered for 4-17 days, and the investigational drug was administered after 3-10 days of itraconazole use. Clinical trials of drug-drug interactions have recently increased due to the development of new drugs and the updated policies regulating drug registration and marketing. Although the designs of clinical trials comply with the new guidelines, the duration of the administration of interacting drugs still varies widely. Optimizing protocol designs can shorten the implementation period of clinical trials and reduce the costs of drug marketing.

Indexed as

Clinical Trials as TopicDrugs, InvestigationalChinaCross-Sectional StudiesDrug InteractionsHumansRifampinDrugs, InvestigationalRifampinClinical trialsDrug-drug interactionsNew drugs

Identifiers

PMID40119410
PMCPMC11929167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.